Advertisement

Topics

Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients

02:15 EST 2 Dec 2016 | GlobalNewsWire (2014)
This article has expired, however you can still download the PDF.
Preview:
Basilea Pharmaceutica AG / Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of th...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...